Wave Life Sciences says GSK selects hepatology siRNA candidate under collaboration, triggering $12 million milestone payment

• Wave Life Sciences’ RNA medicines collaboration with GSK advanced as GSK selected a hepatology siRNA candidate to move into its development pipeline.
• Candidate uses Wave’s GalNAc-siRNA design, triggering a USD 12 million milestone payment to Wave.
• Wave remains eligible for USD 330 million to USD 375 million in development, launch, and commercial milestones per program, with tiered royalties.
• Three additional collaboration programs are progressing toward potential candidate selection.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wave Life Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609300730PRIMZONEFULLFEED9836598) on September 30, 2026, and is solely responsible for the information contained therein.